Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Treats problems with urination caused by an enlarged prostate (benign prostatic hyperplasia or BPH). This medicine is an alpha-blocker.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 1 to 20 of 33

Evaluation of the effectiveness of terazosin, tamsulosin and finasteride for benign prostatic hyperplasia

Bibliographic details: Xiong Y, Ye L, Ren Y, Li Y, Song H, Li N N, Chu Z Z, Li Y P.  Evaluation of the effectiveness of terazosin, tamsulosin and finasteride for benign prostatic hyperplasia. Chinese Journal of Evidence-Based Medicine 2005; 5(6): 448-454, 481

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2005

Tamsulosin as medical expulsive therapy for lower ureterolithiasis: a meta-analysis

Bibliographic details: Liu H, Liu C, Wei W, Liu Z, Tang X.  Tamsulosin as medical expulsive therapy for lower ureterolithiasis: a meta-analysis. Journal of Medical Colleges of PLA 2012; 27(6): 324-333 Available from: http://www.sciencedirect.com/science/article/pii/S1000194813600027

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

[Efficacy of tamsulosin in treatment of upper ureteral calculi: a meta-analysis]

Bibliographic details: Tang G, Wang Y, Zhang R, Zhang R, Xu G, Zhang W.  [Efficacy of tamsulosin in treatment of upper ureteral calculi: a meta-analysis]. Academic Journal of Second Military Medical University 2012; 33(7): 750-754

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Impact of tamsulosin on ureter stone expulsion in korean patients: a meta-analysis of randomized controlled studies

Bibliographic details: Lee JK, Jeong CW, Jeong SJ, Hong SK, Byun SS, Lee SE.  Impact of tamsulosin on ureter stone expulsion in korean patients: a meta-analysis of randomized controlled studies. Korean Journal of Urology 2012; 53(10): 699-704 Available from: http://www.kjurology.org/DOIx.php?id=10.4111/kju.2012.53.10.699

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Tamsulosin as adjunctive treatment after shockwave lithotripsy in patients with upper urinary tract stones: a systematic review and meta-analysis

OBJECTIVE: This study aimed to evaluate the efficacy of tamsulosin as an α(1)-blocker in the treatment of the renal and ureteral stones after shockwave lithotripsy (SWL).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Efficacy of tamsulosin with extracorporeal shock wave lithotripsy for passage of renal and ureteral calculi

This review concluded that tamsulosin adjunctive to extracorporeal shock wave lithotripsy was safe and effective in treating patients with renal stones of 10 to 24mm diameter; evidence was inconclusive for ureteral stone clearance. Given the poor reporting of the review process and lack of adequate primary trial information, the authors' conclusions should be treated with caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Can tamsulosin facilitate expulsion of ureteral stones? A meta-analysis of randomized controlled trials

OBJECTIVES: To determine the efficacy and safety of the adrenergic alpha-antagonist tamsulosin in facilitating ureteral stones expulsion.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Tamsulosin for treatment of unilateral distal ureterolithiasis: a systematic review and meta-analysis

ABSTRACTObjectives:The lifetime prevalence of ureterolithiasis is approximately 13% for men and 7% for women in the United States. Tamsulosin, an α-antagonist, has been used as therapy to facilitate the expulsion of lithiasis. Whether it is a good treatment for distal lithiasis remains controversial. We conducted a systematic review and meta-analysis to evaluate the effect of tamsulosin on the passage of distal ureterolithiasis.Methods:A systematic search was conducted using MEDLINE, EMBASE, and Cochrane Central. Trial eligibility was evaluated by two investigators. All randomized controlled trials (RCTs) comparing tamsulosin to standard therapy or placebo for the treatment of a single distal ureterolithiasis ≤ 10 mm in adult patients with renal colic confirmed by radiographic imaging were included. Data extraction was conducted in duplicate. Primary outcome was the expulsion rate, and secondary outcomes were the mean time for ureterolithiasis expulsion, analgesic requirements, and side effects. Mantel-Haenszel random effect models were used, and heterogeneity was assessed using I2 statistics. Data were presented with relative risks (RRs).Results:The search strategy identified 685 articles, of which 22 studies were included. Combined results suggested a benefit for the expulsion of ureterolithiasis (≤ 10 mm) when tamsulosin was used compared to a standard treatment (RR 1.50 [95% CI 1.31-1.71], I2  =  70%). A decrease in the average time of expulsion of the ureterolithiasis of 3.33 days in favour of tamsulosin was observed (95% CI -4.23, -2.44], I2  =  67%).Conclusion:Tamsulosin increases the rate of spontaneous passage of distal ureterolithiasis (≤ 10 mm).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis

This review concluded that in comparison with placebo, tamsulosin improved international prostate symptom scores and maximum flow rates for patients with benign prostatic hyperplasia with no significant difference in adverse events. A risk of missing data, paucity of evidence and a lack of information regarding study quality suggest that the findings should be interpreted with caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Tamsulosin for ureteral stones: a systematic review and meta-analysis of a randomized controlled trial

The authors concluded that tamsulosin was safe and effective for the expulsion of ureteral stones of less than 10mm. Publication bias, limited reporting of trial quality, significant statistical and clinical variations, and the potential overstatement of the findings due to double counting of participants (acknowledged by the authors), mean that these conclusions seem unlikely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review

The authors concluded that tamsulosin improved International Prostate Symptom Score in the short-term compared to terazosin. High-quality trials were needed to assess the efficacy of tamsulosin in the long term. Some review limitations made the reliability of the pooled results uncertain, but the overall conclusion was suitably cautious and appears appropriate.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Tamsulosin for voiding dysfunction in women

The review concluded that consistent positive findings across multiple clinical trials suggested that in women with lower urinary tract symptoms (particularly those with voiding dysfunction) tamsulosin may be an effective and safe treatment option. The authors? conclusions reflect the evidence presented but limitations in the evidence base make the reliability of the conclusions uncertain.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Fact sheet: Medications for enlarged prostate

Most men who have prostate problems either wait a while to see how their symptoms develop or take medication. Medication is often used when the symptoms are not bad enough to warrant surgery, but have become too bothersome to cope with. The man might have to get up several times a night to urinate, or constantly feel the need to urinate during the day too because his bladder will no longer empty properly. These typical symptoms of an enlarged prostate can become a real burden.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: January 22, 2013

Benign Prostatic Hyperplasia (BPH) Management in Primary Care: Screening and Therapy [Internet]

Benign prostatic hyperplasia (BPH) causes urinary hesitancy and intermittency, weak urine stream, nocturia, frequency, urgency, and the sensation of incomplete bladder emptying. These symptoms, collectively called “lower urinary tract symptoms,” or LUTS, can significantly reduce quality of life. Men with no symptoms or mild symptoms (AUA Symptom Index [SI] score of <7 points), and those who tolerate moderate symptoms well, may be managed without pharmacotherapy (“watchful waiting”). For those who have moderate or severe symptoms, medical treatments include alpha-1-selective adrenergic receptor (a-1-AR) antagonists, 5-alpha-reductase inhibitors (5-aRIs), or a combination therapy with one drug from each of these classes.

Evidence-based Synthesis Program - Department of Veterans Affairs (US).

Version: February 2007
Show search results within this document

A meta-analysis of efficacy and safety of the new alpha 1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.

BACKGROUND: Recently several clinical trials have focused on the efficacy and safety of silodosin, a new, highly selective α1A-blocker. We tried to verify silodosin's superiority to placebo and non-inferiority to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with BPH.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement

PURPOSE: To perform a systematic review and meta-analysis of randomized clinical trials (RCTs) reporting the efficacy and safety of silodosin in the treatment of non-neurogenic male LUTS suggestive of benign prostatic enlargement.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis

PURPOSE: Pharmacological therapy is typically the first-line treatment for patients with benign prostatic hyperplasia (BPH). We carried out a systematic review and meta-analysis to assess the efficacy and safety of silodosin for treating BPH.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

The review concluded that silodosin was effective for lower urinary tract symptoms in men with benign prostatic hyperplasia (non-malignant prostate enlargement), but that the incidence of retrograde ejaculate was higher than with placebo or tamsulosin. The authors appropriately acknowledged that the small volume of short-term evidence of unknown quality may weaken the reliability of their findings, which seems appropriate.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis

PURPOSE: To determine the efficacy and safety of dutasteride, alone or in combination, versus a placebo or control, used for the treatment of benign prostatic hyperplasia.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Management of ureteral calculi and medical expulsive therapy in emergency departments

INTRODUCTION: Ureteral stones are a common problem in daily emergency department practice. Patients may be offered medical expulsive therapy (MET1) to facilitate stone expulsion and this should be offered as a treatment for patients with distal ureteral calculi, who are amenable to waiting management. Emergency department clinicians and family practitioners are often in the front line regarding the diagnosis and treatment of symptomatic nephrolithiasis and this commentary is dedicated to them because their decisions directly influence the outcome of the acute stone episode and appropriate referral patterns.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Systematic Reviews in PubMed

See all (70)...